Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MicroRNAs01:22

MicroRNAs

21.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.0K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

808
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
808
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

16.3K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.3K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

209
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
209
Experimental RNAi02:15

Experimental RNAi

6.0K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AI counseling agent for motivational interviewing: Conversational processes associated with change talk in emergency department patients.

Journal of substance use and addiction treatment·2026
Same author

TFG-Containing Fusions in Melanocytic Tumors: From Polymorphic Read-Through Transcripts to Oncogenic Kinase Fusions.

Journal of cutaneous pathology·2026
Same author

From Symptoms to Signatures: Proteome-Defined Endotypes in Functional Dyspepsia.

Neurogastroenterology and motility·2026
Same author

Immunometabolic remodeling of perivascular adipose tissue in murine lupus: implications for lupus vasculopathy.

bioRxiv : the preprint server for biology·2026
Same author

Developing a Clinically Practical Biomaterial Platform for Endogenous Liver Regeneration.

Gels (Basel, Switzerland)·2026
Same author

Multidimensional Predictors of Tirzepatide Efficacy: Clinical, Genetic, and Molecular Biomarkers for Glycemic, Weight, and Organ Protection.

Pharmaceuticals (Basel, Switzerland)·2026

Related Experiment Video

Updated: May 11, 2025

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization
08:22

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Published on: September 15, 2018

8.1K

microRNAs in Type 1 Diabetes: Roles, Pathological Mechanisms, and Therapeutic Potential.

Hayeong Cho1, Se Eun Ha1, Rajan Singh1

  • 1Department of Physiology & Cell Biology, University of Nevada School of Medicine, Reno, NV 89557, USA.

International Journal of Molecular Sciences
|April 17, 2025
PubMed
Summary
This summary is machine-generated.

Regulatory microRNAs (miRNAs) are key in Type 1 diabetes (T1D) pathogenesis. This review explores how targeting miRNAs could offer new therapies to restore pancreatic beta-cell function and halt T1D progression.

Keywords:
apoptosisautoimmune diseasemiRNAstype 1 diabetesβ-cells

More Related Videos

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

5.6K
Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
07:01

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models

Published on: May 10, 2022

1.5K

Related Experiment Videos

Last Updated: May 11, 2025

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization
08:22

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Published on: September 15, 2018

8.1K
Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

5.6K
Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
07:01

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models

Published on: May 10, 2022

1.5K

Area of Science:

  • Endocrinology
  • Immunology
  • Molecular Biology

Background:

  • Type 1 diabetes (T1D) is an autoimmune disease causing pancreatic beta-cell destruction and insulin deficiency.
  • Current treatments manage symptoms but do not prevent disease progression or beta-cell loss.
  • Autoimmune processes and chronic inflammation drive beta-cell destruction in T1D.

Purpose of the Study:

  • To review the role of microRNAs (miRNAs) in Type 1 diabetes pathogenesis.
  • To explore miRNA dysregulation in both animal models and human patients with T1D.
  • To assess the therapeutic potential of targeting miRNAs for T1D treatment.

Main Methods:

  • Literature review of studies on miRNAs in T1D.
  • Analysis of miRNA expression profiles in diabetic animal models.
  • Examination of miRNA involvement in human T1D pathogenesis.

Main Results:

  • MicroRNAs (miRNAs) are critical regulators of gene expression involved in T1D.
  • Dysregulated miRNAs are implicated in the autoimmune destruction of pancreatic beta-cells.
  • Specific miRNA profiles are observed in diabetic animal models and human patients.

Conclusions:

  • MicroRNAs (miRNAs) represent potential diagnostic biomarkers for T1D.
  • Targeting dysregulated miRNAs offers a promising therapeutic strategy for T1D.
  • miRNA-based therapies could restore beta-cell function and slow disease progression.